Company intelligence / Profile preview

Zhejiang Shimai Pharmaceutical Co., Ltd.

Hangzhou, Zhejiang, Chinacentrymed.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has multiple programs in clinical development, with three products in Phase 2 clinical trials (CMD-011, SMET-12, DNV-3) and several others in preclinical and Phase 1 stages. Their lead candidates target various cancers including hepatocellular carcinoma, non-small cell lung cancer, and melanoma.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyBispecific antibodyBispecific T-cell Engager (BiTE)Trispecific antibody
Industry: Biotech

Partnerships

Betta Pharmaceuticals Co., Ltd.

Beyond the preview

Go deeper on Zhejiang Shimai Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Shimai Pharmaceutical Co., Ltd..